18
Aug

Danish financial regulators took a dim view of Novo Nordisk’s decision to spend the weekend pondering the FDA’s February, 2013 snub to Tresiba before spreading the news of the agency’s complete response letter and the major delay that would be triggered by its demand for a new study. And today Novo said it had decided to accept a $90,000 fine to close the books on the incident, not the least bit chastened at the slap on the hand.

…read more

Source: Novo Nordisk accepts a $90K slap on the hand for delaying news of Tresiba setback

    

0 No comments